In contrast, the immune-activated subtype, which exhibits spatial co-option of PD-L1+ cancer cells and pro-inflammatory signatures, shows durable responses to immunotherapy and may benefit from the combination of immune checkpoint inhibitors (ICI) and MET-TKIs (18). Here, MET is linked to cancer.